Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Brett J CarrollSmith Center for Cardiovascular Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center Harvard Medical School Boston MA USA.ORCID 0000-0002-6704-5663
Samuel Z GoldhaberDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0002-6450-0448
Zhou LanThrombosis Research Group, Brigham and Women's Hospital Harvard Medical School Boston MA USA.
Gregory PiazzaDivision of Cardiovascular Medicine, Brigham and Women's Hospital Harvard Medical School Boston MA USA.ORCID 0000-0003-1407-5276
CORONA‐VTE Network Investigators
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
backgroundPatients with COVID-19 are at risk of thrombotic and cardiovascular complications. Existing risk estimates derive from early COVID-19 experiences. More recent event rates, temporal trends, and the association between vaccination status and cardiovascular outcomes remain unclear.
methodsThe CORONA-VTE Network (COVID-19 Registry to Assess Frequency, Risk Factors, Management, and Outcomes of Arterial and Venous Thromboembolic Complications) multicenter registry included patients with COVID-19 from March 2020 to February 2024. A composite of venous and arterial thrombotic events and a composite of adjudicated cardiovascular events were assessed at 90 days after COVID-19 diagnosis. Time-to-first-event analyses were stratified by inpatients and outpatients and adjusted for competing risks. Outcomes were adjudicated by independent physicians.
resultsOf 11 165 patients, 4451 were inpatients (mean age, 65 years; 47% women) and 462 of 4451 were admitted to the intensive care unit. Among inpatients, the 90-day cumulative incidences of thrombotic and cardiovascular events were 8.9% (95% CI, 8.0%-9.8%) and 15.6% (95% CI, 14.5%-16.7%), respectively. Corresponding estimates for patients in the intensive care unit were 20.0% (95% CI, 16.6%-24.0%) and 30.7% (95% CI, 26.8%-35.3%), while event rates were low among outpatients. There was an initial decline in cardiovascular events (adjusted hazard ratio [HR], 0.84;
conclusionsThrombotic and cardiovascular events are common in hospitalized patients with COVID-19, especially those in the intensive care unit, without a persistent decline over time. COVID-19 vaccination was associated with a reduced risk of cardiovascular events.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Adjudicated Cardiovascular Events in Patients With COVID-19: Association With Vaccination Status and Changes over Time. · full record | Socratic